BiotechTube
aTENSION.life

aTENSION.life

Vienna, Austria· Est. 2020

aTENSION.life is on a mission to redefine hypertension care through precision diagnostics and personalized treatment. Their core innovation is the ALDO+ platform, which uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) to directly measure key hypertension hormones (Angiotensin I, Angiotensin II, Aldosterone) from a single blood sample, enabling accurate screening for secondary hypertension causes like primary aldosteronism. The company's unique Prep 'n' Ship™ operational model bridges the gap between labs with and without mass spectrometry capabilities, creating a scalable network for advanced hypertension diagnostics. By addressing the critical under-diagnosis of secondary hypertension, aTENSION aims to improve patient outcomes and reduce cardiovascular risks through targeted therapy.

atension.life

Private Company

Funding information not available

AI Company Overview

aTENSION.life is on a mission to redefine hypertension care through precision diagnostics and personalized treatment. Their core innovation is the ALDO+ platform, which uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) to directly measure key hypertension hormones (Angiotensin I, Angiotensin II, Aldosterone) from a single blood sample, enabling accurate screening for secondary hypertension causes like primary aldosteronism. The company's unique Prep 'n' Ship™ operational model bridges the gap between labs with and without mass spectrometry capabilities, creating a scalable network for advanced hypertension diagnostics. By addressing the critical under-diagnosis of secondary hypertension, aTENSION aims to improve patient outcomes and reduce cardiovascular risks through targeted therapy.

CardiovascularEndocrinologyHypertension

Technology Platform

Mass spectrometry-based diagnostic platform (LC-MS/MS) for direct quantification of Renin-Angiotensin-Aldosterone System (RAAS) hormones (Angiotensin I, Angiotensin II, Aldosterone) from blood samples, enabling precision screening for secondary hypertension causes like primary aldosteronism.

Opportunities

Significant growth opportunity exists in addressing the massively under-screened population for secondary hypertension (only 1-2% screened currently).
Expansion of the Prep 'n' Ship™ laboratory network creates scalable distribution, while potential guideline changes recommending broader screening could dramatically increase market size.
Additional opportunities include expanding the test menu to related endocrine disorders and developing companion diagnostics for hypertension therapies.

Risk Factors

Key risks include adoption barriers in changing clinical practice patterns, reimbursement challenges with insurance payers, competitive response from larger diagnostic companies, regulatory requirements for distributed testing networks, and the need for substantial market education about primary aldosteronism recognition and screening.

Competitive Landscape

Competes against traditional ELISA-based immunoassays from large diagnostics companies (Siemens, Abbott, Roche) which have inferior analytical performance. Differentiates through mass spectrometry technology providing direct hormone measurement with less drug interference, validated clinical accuracy for primary aldosteronism screening, and the unique Prep 'n' Ship™ business model enabling widespread access without capital investment in equipment.